BC Innovations | Nov 14, 2019
Tools & Techniques

Weizmann 10K Project aims for -omics sweet spot

Using structured and unstructured learning, the Weizmann Institute’s Eran Segal wants to mine reams of data over 20 years from 10,000 people who start out healthy, to find the markers that signal disease. His 10K...
BioCentury | Oct 17, 2019
Emerging Company Profile

Parker Institute’s ArsenalBio launches with $85M to build cell engineering war chest

ArsenalBio launched Thursday with $85 million in a series A round to combine the technologies of its six Parker Institute co-founders into a suite of tools the company thinks could overcome key hurdles to cell...
BC Week In Review | Mar 29, 2019
Company News

Guardant Health to acquire fellow cancer diagnostic company Bellwether Bio

Liquid biopsy company Guardant Health said it will advance its early detection product pipeline by acquiring Bellwether Bio for an undisclosed sum. Bellwether Bio Inc. (Seattle, Wash.) is developing cancer diagnostics based on the epigenomics...
BC Innovations | Jan 18, 2019
Targets & Mechanisms

Exploring 3-D genomic white space

Gene regulation is offering a new class of targets that operate on a higher level than DNA sequences and epigenetic markers: 3-D genomic structures. While strategies to drug the 3-D genome are still in their...
BC Innovations | Feb 22, 2018

Bigger BRAIN Initiative

The Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative is preparing to push projects in three areas past the pilot phase with $169 million in new NIH grants announced in 4Q17. The aim is to...
BC Week In Review | Apr 28, 2017
Company News

Epigenomics, Cathay Fortune deal

Cathay's Blitz F16-83 GmbH subsidiary will acquire molecular diagnostics company Epigenomics for €7.52 per share, or about €171 million ($185.6 million) in cash. The price is a 52% premium on Epigenomics' closing price of €4.95...
BC Extra | Apr 26, 2017
Company News

Chinese PE firm to acquire Epigenomics

A subsidiary of Chinese private equity firm Cathay Fortune International Co. Ltd. will acquire molecular diagnostics company Epigenomics AG (Xetra:ECX; OTCQX:EPGNY) for €7.52 per share, or about €171 million ($185.6 million) in cash. The subsidiary,...
BC Extra | Dec 3, 2016
Company News

Management tracks

Prescription and OTC pharma Taro Pharmaceutical Industries Ltd. (NYSE:TARO) said Uday Baldota will replace Kal Sundaram as its CEO, effective April 2017. Baldota is EVP and CFO at Sun Pharmaceutical Industries Ltd. (BSE:524715; NSE:SUNPHARMA). Abhay...
BioCentury | Jul 11, 2016

Shedding red

Steve Edelson, Senior Editor   Brexit nearly wiped out what looked to be a rebound quarter for biotech. Only two market cap segments finished in positive territory, and smaller companies continued to get pounded. Big...
BC Extra | Jul 1, 2016
Company News

Management tracks

Molecular diagnostics company Epigenomics AG (Xetra:ECX) named Gregory Hamilton CEO. He replaces CEO and CFO Thomas Taapken, who has left the company. Hamilton was CEO at AltheaDx Inc. (San Diego, Calif.). The company expects to...
Items per page:
1 - 10 of 257